| Topic | Key points | Evidence/citations |
|---|---|---|
| Identity verification | Rat **Aga** corresponding to **UniProt P30919** is the lysosomal enzyme **aspartylglucosaminidase / glycosylasparaginase / N(4)-(β-N-acetylglucosaminyl)-L-asparaginase** in the **Ntn-hydrolase** family; literature on mammalian AGA aligns with this identity and should be distinguished from unrelated genes/proteins using similar symbols. | Mammalian AGA/glycosylasparaginase identity and lysosomal role are explicitly described, with rat liver enzyme used as a biochemical reference (pqac-00000002, pqac-00000004) |
| Enzyme name and EC reaction | **EC 3.5.1.26**; AGA is a lysosomal amidase that hydrolyzes the **Asn-GlcNAc amide bond** in glycoasparagines during glycoprotein degradation. The reaction is commonly described as cleavage of **aspartylglucosamine (GlcNAc-Asn)** to release aspartate and amino-sugar products in the final steps of N-linked glycoprotein catabolism. | Direct EC assignment and bond specificity described for mammalian AGA; AGU results from failure of this reaction (pqac-00000002, pqac-00000004, pqac-00000005) |
| Substrate specificity | Natural substrate specificity requires a **glycosylated L-asparagine** with free **α-amino** and **α-carboxyl** groups. AGA acts on **GlcNAc-Asn/aspartylglucosamine** and larger glycoasparagines, but does **not** hydrolyze **fucosylated complex-type N-glycans** efficiently. It also shows ancillary **L-asparaginase** and **β-aspartyl peptide** hydrolysis/synthesis activities, though glycoasparagine cleavage is its principal physiological role. | Substrate rules and exclusions summarized from biochemical characterization and dissertation review of AGA activation/function (pqac-00000001, pqac-00000003, pqac-00000004, pqac-00000007) |
| Activation and processing | AGA is synthesized as a **346-aa precursor** with an N-terminal **23-aa signal peptide** removed co-translationally. Precursor molecules dimerize and undergo **autocatalytic cleavage** between **Asp205-Thr206**, generating **α** and **β** subunits; cleavage exposes the catalytic **N-terminal Thr206** nucleophile required for activity. Proper conversion into subunits is essential, as AGU-causing mutations can abolish both processing and catalysis. | Processing pathway, signal peptide, autocleavage, and Thr nucleophile are directly described; disease mutations blocking subunit conversion support this mechanism (pqac-00000000, pqac-00000002, pqac-00000003, pqac-00000006, pqac-00000007) |
| Quaternary structure | Mature AGA assembles as an active **αβ heterodimer** or more commonly an **α2β2 / (αβ)2 tetramer**, depending on species and preparation. Rat liver AGA was classically characterized as a **49-kDa heterodimer**, whereas human enzyme is often described as an **αββα tetramer**. | Species-dependent oligomeric state and rat liver heterodimer evidence are summarized in biochemical sources (pqac-00000001, pqac-00000002) |
| Subcellular localization and trafficking | AGA is a **soluble lysosomal hydrolase**. It is **N-glycosylated**, trafficked to lysosomes through the **mannose-6-phosphate (M6P) pathway**, and extracellular enzyme can be **endocytosed via M6P receptors**. In neurons, AGA localizes to soma and processes but is not prominent in nerve terminals. | Lysosomal localization, glycosylation/M6P trafficking, and receptor-mediated uptake are directly reported (pqac-00000000, pqac-00000003, pqac-00000005, pqac-00000006) |
| Key rat-specific biochemical facts | Rat AGA was purified from **rat liver**; purified rat liver glycosylasparaginase is reported as a **49-kDa heterodimer** with subunits around **24 kDa (α)** and **20 kDa (β)**. Rat/mouse AGA show reported **pH optima ~7-9**, contrasting with the more acidic optimum reported for human AGA. Rat liver enzyme stability was estimated at about **2 days half-life** in cells. | Rat liver purification, subunit sizes, pH optimum, and half-life are specifically noted in rat-focused biochemical summaries (pqac-00000000, pqac-00000002, pqac-00000004) |
| Biological pathway/function | AGA acts in the **lysosomal degradation pathway of N-linked glycoproteins**, catalyzing a terminal amide-bond hydrolysis step after upstream exoglycosidases/processing events. Its action prevents accumulation of glycoasparagine breakdown intermediates. | Role in glycoprotein catabolism and consequence of deficiency are consistently described across mechanistic and disease literature (pqac-00000002, pqac-00000004, pqac-00000005) |
| Disease relevance | AGA deficiency causes **aspartylglucosaminuria (AGU)**, a lysosomal storage disorder characterized by accumulation of **uncleaved glycoasparagines/aspartylglucosamine** in tissues and body fluids. Mutations that impair folding, dimerization, autocleavage, or lysosomal maturation abolish enzyme activity. | AGU disease mechanism and mutation-processing relationship are directly documented (pqac-00000002, pqac-00000005, pqac-00000006, pqac-00000013) |
| Quantitative therapeutic threshold | Foundational preclinical work indicates that increasing intracellular AGA activity to only about **3-4% of normal** can clear intracellular aspartylglucosamine in cultured AGU cells, suggesting a relatively low correction threshold for biochemical rescue. | Quantitative rescue threshold summarized in AGU review (pqac-00000013) |
| 2023 development: validated serum biomarker assay | A 2023 validated fluorometric serum assay established **AGA activity** as a practical biomarker for AGU diagnostics and clinical studies. Reported assay performance: **LLOQ 4.8 pmol AMC = 0.18 mU/L**; AGU patient serum averaged **0.11 mU/L** (range **0.0123-0.251**), versus healthy donors **3.252 mU/L** (range **2.503-3.897**). The assay used **12.5 µM Asp-AMC**, **24 h** incubation, and distinguished patients unambiguously from controls. **Publication date:** Mar 2023. **URL:** https://doi.org/10.3390/ijms24065722 | Quantitative validation data and assay formula from the 2023 study (pqac-00000009, pqac-00000010, pqac-00000011, pqac-00000016, pqac-00000017) |
| 2023 development: glycoengineered lysosomal enzyme platform | A 2023 **Long-Acting-GlycoDesign (LAGD)** study included **AGA** among lysosomal enzymes successfully glycoengineered to convert **M6P-containing N-glycans** to **complex sialylated N-glycans**, with the goal of extending circulatory stability and improving biodistribution of replacement enzymes. The paper states that LAGD extended plasma half-life for tested enzymes including **AGA** in wild-type mice, though the detailed numeric tissue data shown in the excerpt were for GLA rather than AGA. **Publication date:** Feb 2023. **URL:** https://doi.org/10.3389/fbioe.2023.1128371 | AGA inclusion in the glycoengineering platform and extended half-life claim are described in the article metadata/abstract and surrounding methods/results text (pqac-00000014, pqac-00000015) |
| 2023 development: gene therapy outlook | A 2023 review of gene therapy for lysosomal storage diseases lists **AGU/AGA** among disorders of interest and emphasizes that CNS disease remains a major challenge for conventional therapies, increasing interest in **AAV-based** approaches. AGA/AGU is discussed in the context of preclinical progress and the broader movement toward clinical translation for neurological lysosomal diseases. **Publication date:** Jan 2023. **URL:** https://doi.org/10.3389/fgene.2023.1064924 | Review-level therapeutic context for AGA/AGU gene therapy (pqac-00000008) |
| Real-world/implementation relevance | Current real-world utility is strongest for **diagnostics and biomarker monitoring** rather than approved disease-specific therapy: serum AGA activity assays, urinary oligosaccharide/GlcNAc-Asn analysis, and genetic testing are clinically relevant, while ERT/gene therapy remain largely preclinical or translational for AGU. | Diagnostic implementation and emerging therapy-monitoring rationale are summarized in recent assay paper and AGU review (pqac-00000008, pqac-00000011, pqac-00000013) |


*Table: This table summarizes the verified identity, enzymatic function, lysosomal trafficking, rat-specific biochemical properties, disease relevance, and recent translational developments for rat Aga/AGA (UniProt P30919). It is useful as a compact evidence map linking functional annotation to primary and recent literature.*